Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Free Cash Flow (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Free Cash Flow for 16 consecutive years, with $41.9 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 43.65% to $41.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $184.2 million through Dec 2025, up 190.09% year-over-year, with the annual reading at $184.2 million for FY2025, 190.09% up from the prior year.
  • Free Cash Flow hit $41.9 million in Q4 2025 for Ani Pharmaceuticals, up from $38.0 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $71.8 million in Q2 2025 to a low of -$19.2 million in Q1 2022.
  • Historically, Free Cash Flow has averaged $16.8 million across 5 years, with a median of $18.6 million in 2023.
  • Biggest five-year swings in Free Cash Flow: plummeted 1564.63% in 2022 and later soared 15080.8% in 2025.
  • Year by year, Free Cash Flow stood at -$12.5 million in 2021, then skyrocketed by 62.94% to -$4.6 million in 2022, then skyrocketed by 1197.27% to $51.0 million in 2023, then crashed by 42.8% to $29.2 million in 2024, then surged by 43.65% to $41.9 million in 2025.
  • Business Quant data shows Free Cash Flow for ANIP at $41.9 million in Q4 2025, $38.0 million in Q3 2025, and $71.8 million in Q2 2025.